PHILADELPHIA, PA--(Marketwire - January 29, 2009) - Eurand N.V. (NASDAQ: EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies, announced today that it is scheduled to present at the upcoming Deutsche Bank Securities Small- and Mid-Cap Conference. John Fraher, Eurand’s Chief Commercial Officer, will be presenting.
Event: Deutsche Bank Securities Small- and Mid-Cap Conference Date: Thursday, February 12, 2009 Time: 9:20 a.m. ET Location: The Ritz Carlton, Naples, Naples, Fla.
An audio webcast of the presentation will be available by accessing the investor relations section of Eurand’s web site at www.eurand.com. A replay of the presentation will be available until March 12, 2009.
About Eurand
Eurand is a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies. Eurand has had four products approved by the FDA since 2001 and has a pipeline of product candidates in development for itself and its collaboration partners. Its technology platforms include bioavailability enhancement of poorly soluble drugs, custom release profiles, taste-masking orally disintegrating tablet (ODT) formulations, and drug conjugation.
Eurand is a global company with facilities in the U.S. and Europe. For more information, visit Eurand’s website at www.eurand.com.
Contacts:
Bill Newbould
Vice President, Investor Relations
Eurand N.V.
+1 267-759-9335
Email Contact
Nick Laudico/Sara Ephraim
The Ruth Group
+1 646-536-7030/7002
Email Contact
Email Contact
